Transplantation for myelodysplastic syndromes 2013

Current Opinion in Hematology

Volumn 20, Issue 6, 2013, Pages 494-500

  Vaughn, Jennifer E ^a   Scott, Bart L ^a   Deeg, H Joachim ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

allogeneic haematopoietic cell transplantation; conditioning regimens; cytogenetics; hypomethylating agents; myelodysplastic syndromes; relapse

Indexed keywords

AZACITIDINE; FLUDARABINE; MIDOSTAURIN; MOLECULAR MARKER; QUIZARTINIB; TREOSULFAN;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER SURVIVAL; CHIMERA; COMORBIDITY; CYTOGENETICS; DECISION MAKING; DISEASE COURSE; DONOR LYMPHOCYTE INFUSION; FOLLOW UP; GENE MUTATION; GRAFT VERSUS HOST REACTION; HLA SYSTEM; HUMAN; INDUCTION CHEMOTHERAPY; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; KARYOTYPE; LYMPHATIC LEUKEMIA; MASS SPECTROMETRY; MINIMAL RESIDUAL DISEASE; MONOSOMY; MORTALITY; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PATHOPHYSIOLOGY; POPULATION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; REDUCED INTENSITY CONDITIONING; RELAPSE; REVIEW; RISK FACTOR; SALVAGE THERAPY; UNRELATED DONORS;

AGE FACTORS; COMORBIDITY; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KARYOTYPE; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RECURRENCE; TRANSPLANTATION CONDITIONING;

EID: 84885400184     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e328364f547     Document Type: Review

References (54)

1. Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010; 363:2091-2101.
2. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes [erratum appears in Blood 1998 Feb 1;91(3):1100]. Blood 1997; 89:2079-2088.
3. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012; 120:2454-2465.
4. Malcovati L, Della Porta MG, Strupp C, et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica 2011; 96:1433-1440.
5. Deeg HJ, Scott BL, Fang M, et al. Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS. Blood 2012; 120:1398-1408.
6. Breems DA, van Putten WL, De Greef GE, et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol 2008; 26:4791-4797.
7. Patnaik MM, Hanson CA, Hodnefield JM, et al. Monosomal karyotype in myelodysplastic syndromes, with or without monosomy 7 or 5, is prognos-tically worse than an otherwise complex karyotype. Leukemia 2011; 25:266-270.
8. Belli CB, Bengio R, Aranguren PN, et al. Partial and total monosomal karyotypes in myelodysplastic syndromes: comparative prognostic relevance among 421 patients. Am J Hematol 2011; 86:540-545.
9. Schanz J, Tuchler H, Sole F, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 2012; 30:820-829.
10. Valcarcel D, Adema V, Sole F, et al. Complex, not monosomal, karyotype is the cytogenetic marker of poorest prognosis in patients with primary myelodys-plastic syndrome. J Clin Oncol 2013; 31:916-922.
11. Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011; 364:2496-2506.
12. Garcia-Manero G, Shan J, Faderl S, et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia 2008; 22:538-543.
13. Walter MJ, Ding L, Shen D, et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 2011; 25:1153-1158.
14. Papaemmanuil E, Cazzola M, Boultwood J, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 2011; 365:1384-1395.
15. Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011; 478:64-69.
16. Graubert TA, Shen D, Ding L, et al. Recurrent mutations in the U2AF1 splicing & factor in myelodysplastic syndromes. Nat Genet 2012; 44:53-57. Spliceosome mutations are the most frequent mutations inMDS and correlate with disease phenotype.
17. Bejar R, Stevenson KE, Caughey BA, et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 2012; 30:3376-3382.
18. Sierra J, Pérez WS, Rozman C, et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 2002; 100:1997-2004.
19. Warlick ED, Cioc A, DeFor T, et al. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden. Biol Blood Marrow Transplant 2009; 15:30-38.
20. Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004; 104:579-585.
21. Kuendgen A, Strupp C, Aivado M, et al. Myelodysplastic syndromes in patients younger than age 50. J Clin Oncol 2006; 24:5358-5365.
22. Scott BL, Storer B, Loken M, et al. Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome. Biol Blood Marrow Transplant 2005; 11:65-73.
23. Nakai K, Kanda Y, Fukuhara S, et al. Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome. Leukemia 2005; 19:396-401.
24. Estey E, de Lima M, Tibes R, et al. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood 2007; 109: 1395-1400.
25. Gerds AT, Gooley TA, Estey EH, et al. Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS. Biol Blood Marrow Transplant 2012; 18:1211-1218.
26. Damaj G, Duhamel A, Robin M, et al. Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-Francophone des Myelodysplasies. J Clin Oncol 2012; 30:4533-4540.
27. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106:2912-2919.
28. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91:756-763.
29. Scott BL, Sandmaier BM, Storer B, et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 2006; 20:128-135.
30. Martino R, de Wreede L, Fiocco M, et al. Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with <10% BM blasts: a report from EBMT. Bone Marrow Transplant 2013; 48:761-770.
31. Luger SM, Ringdén O, Zhang M-J, et al. Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplant 2012; 47:203-211.
32. Nemecek ER, Guthrie KA, Sorror ML, et al. Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. Biol Blood Marrow Transplant 2011; 17: 341-350.
33. Deeg HJ, Storer B, Slattery JT, et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 2002; 100:1201-1207.
34. Flomenberg N, Baxter-Lowe LA, Confer D, et al. Impact of HLA class I and class II high resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplant outcome. Blood 2004; 104:1923-1930.
35. Mielcarek M, Storer BE, Sandmaier BM, et al. Comparable outcomes after nonmyeloablative hematopoietic cell transplantation with unrelated and related donors. Biol Blood Marrow Transplant 2007; 13:1499-1507.
36. Ho VT, Kim HT, Aldridge J, et al. Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011; 17:1196-1204.
37. Saber W, Cutler C, Nakamura R, et al. Comparison of outcomes after related and unrelated hematopoietic cell transplantation in adults with myelodysplas-tic syndromes: a report from the Center for International Blood and Marrow Transplant Research (CIBMTR). Blood 2013. [Epub ahead of print]
38. Alousi AM, Le-Rademacher J, Saliba RM, et al. Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer? Blood 2013; 121:2567-2573.
39. Ooi J, Iseki T, Takahashi S, et al. Unrelated cord blood transplantation for adult patients with advanced myelodysplastic syndrome. Blood 2003; 101:4711-4713.
40. Sato A, Ooi J, Takahashi S, et al. Unrelated cord blood transplantation after myeloablative conditioning in adults with advanced myelodysplastic syndromes. Bone Marrow Transplant 2011; 46:257-261.
41. Di Bartolomeo P, Santarone S, De Angelis G, et al. Haploidentical, unmani-pulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies. Blood 2013; 121:849-857.
42. Aversa F, Terenzi A, Tabilio A, et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005; 23:3447-3454.
43. Anasetti C, Logan BR, Lee SJ, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med 2012; 367:1487-1496.
44. Appelbaum FR. Pursuing the goal of a donorfor everyone in need [Comment]. N Engl J Med 2012; 367:1555-1556.
45. Chang CK, Storer BE, Scott BL, et al. Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders. Blood 2007; 110:1379-1387.
46. Litzow MR, Tarima S, Perez WS, et al. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood 2010; 115:1850-1857.
47. Mielcarek M, Storer BE, Flowers MED, et al. Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hema-topoietic cell transplantation. Biol Blood Marrow Transplant 2007; 13: 1160-1168.
48. de Lima M, Giralt S, Thall PF, et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer 2010; 116:5420-5431.
49. Vaughn J, Storer B, Mielcarek M, et al. Treatment of recurrent or persistent AML/MDS after allogeneic hematopoietic cell transplantation with azacitidine [abstract]. Blood 2010; 116:551; abstr. 1288.
50. Platzbecker U, Wermke M, Radke J, et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia 2012; 26:381-389.
51. Adams JA, Barrett AJ. Haematopoietic stimulators in the serum of patients with severe aplastic anaemia. Br J Haematol 1982; 52:327-335.
52. Schmid C, Schleuning M, Ledderose G, et al. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005; 23: 5675-5687.
53. Campregher PV, Gooley T, Scott BL, et al. Results of donor lymphocyte infusions for relapsed myelodysplastic syndrome after hematopoietic cell transplantation. Bone Marrow Transplant 2007; 40:965-971.
54. Prebet T, Gore SD, Esterni B, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol 2011; 29:3322-3327.